Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus
/in International Publications, Newcastle Disease Virus /von 2021-03-30 / Int J Med Sci 2021;18(11):2294-2302The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2021-02-01 / Neurosurg Focus 2021 02;50(2):E8Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice
/in Colorectal Cancer, International Publications, Newcastle Disease Virus /von 2020-12-08 / PeerJ 2020;8:e9761Newcastle Disease Virus at the Forefront of Cancer Immunotherapy
/in International Publications, Newcastle Disease Virus /von 2020-11-28 / Cancers (Basel) 2020 Nov;12(12)Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2020-11-16 / Int J Mol Sci 2020 Nov;21(22)Emerging Immunotherapies in the Treatment of Brain Metastases
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2020-10-26 / Oncologist 2020 Oct;Evaluation of Apoptosis Induction by Newcastle Disease Virus LaSota Strain in Human Breast Carcinoma Cells
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2020-10-01 / Arch Razi Inst 2020 10;75(3):367-376NDV-D90 inhibits 17β-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2020-09-28 / J Cell Biochem 2021 Jan;122(1):3-15
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
- Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma; a single center phase I/II trial
- MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells